By Mill Chart
Last update: Feb 28, 2024
In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.
ChartMill assigns a Technical Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple technical indicators and properties.
Overall AMPH gets a technical rating of 8 out of 10. This is due to a consistent overall performance, although we see some doubts in the very recent evolution. In the medium time frame things are still looking good.
Check the latest full technical report of AMPH for a complete technical analysis.
Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.
We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 202 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make AMPH suitable for value and growth investing!
For an up to date full fundamental analysis you can check the fundamental report of AMPH
Our CANSLIM screen will find you more ideas suited for growth investing.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (4/24/2024, 7:00:00 PM)
After market: 41 0 (0%)41
+0.09 (+0.22%)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.